Core Scientific Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Core Scientific şirketinin toplam hissedar öz sermayesi $-418.7M ve toplam borcu $850.3M olup, bu da borç-öz sermaye oranını -203.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $705.5M ve $1.1B dir.

Anahtar bilgiler

-203.1%

Borç/özkaynak oranı

US$850.32m

Borç

Faiz karşılama oranı	n/a
Nakit	US$42.15m
Eşitlik	-US$418.73m
Toplam yükümlülükler	US$1.12b
Toplam varlıklar	US$705.46m

Son finansal sağlık güncellemeleri

Recent updates

Core Scientific: A Solid Bitcoin Mining Play

Oct 11

Core Scientific: A Buy On Leading Bitcoin Production Numbers

Aug 11

Core Scientific July bitcoin production rose 10.4% M/M with new deployments and multiple facilities

Aug 05

Core Scientific signs $100M in committed equity facility for enhancing liquidity

Jul 21

Why I'm Very Optimistic On Core Scientific's Future

Jun 10

Robust Earnings May Not Tell The Whole Story For Core Scientific (NASDAQ:CORZ)

Apr 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CORZ.Q negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: CORZ.Q şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CORZ.Q negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: CORZ.Q 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan CORZ.Q mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: CORZ.Q kârlı değildir ancak serbest nakit akışı pozitif olsa ve yılda 11.1 % oranında azalsa bile 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Core Scientific Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Core Scientific, Inc. Emerged from Bankruptcy

Core Scientific, Inc. Com Deleted from OTC Equity

Modified Fourth Amended Joint Reorganization Plan and Disclosure Statement Approved for Core Scientific, Inc.

Amended Reorganization Plan Filed by Core Scientific, Inc.

Core Scientific, Inc. announced delayed 10-Q filing

Core Scientific's Common Stock to Be Delisted from Nasdaq

Recent updates

Core Scientific, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Core Scientific, Inc. to Report Q2, 2024 Results on Aug 07, 2024

CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ).

Core Scientific, Inc. to Report Q1, 2024 Results on May 08, 2024

Core Scientific, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

Core Scientific, Inc. Emerged from Bankruptcy

Core Scientific, Inc. Com Deleted from OTC Equity

Modified Fourth Amended Joint Reorganization Plan and Disclosure Statement Approved for Core Scientific, Inc.

Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million.

Amended Reorganization Plan Filed by Core Scientific, Inc.

Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million.

Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million.

Core Scientific, Inc. announced that it expects to receive $53.9 million in funding from Bitmain Technologies Limited

Core Scientific, Inc. Appoints Adam Sullivan as Chief Executive Officer

Core Scientific, Inc. Appoints Adam Sullivan as President

Core Scientific, Inc. announced delayed 10-Q filing

Core Scientific, Inc.(OTCPK:CORZ.Q) dropped from NASDAQ Composite Index

Core Scientific's Common Stock to Be Delisted from Nasdaq

Core Scientific, Inc. Filed for Bankruptcy

Core Scientific Receives A Written Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price Requirement

Stacie Olivares Resigns as A Director of Core Scientific, Inc

Core Scientific, Inc. Appoints Todd Duchene as President and Chief Legal Officer, Effective November 14, 2022

Core Scientific, Inc. announced delayed 10-Q filing

Core Scientific, Inc Contemplates Bankruptcy

Core Scientific, Inc. Announces Management Changes

Core Scientific: A Solid Bitcoin Mining Play

Core Scientific, Inc. announced delayed 10-Q filing

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Core Scientific, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2022

Core Scientific: A Buy On Leading Bitcoin Production Numbers

Core Scientific July bitcoin production rose 10.4% M/M with new deployments and multiple facilities

Core Scientific, Inc. announced that it expects to receive $100 million in funding from B. Riley Principal Capital II, LLC

Core Scientific signs $100M in committed equity facility for enhancing liquidity

Price target decreased to US$8.02

Core Scientific, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus EPS estimates fall by 13%

Why I'm Very Optimistic On Core Scientific's Future

Price target decreased to US$11.00

Co-Founder recently sold US$9.0m worth of stock

Consensus forecasts updated

Core Scientific, Inc. Provides Operating Guidance for the Year 2022

Price target decreased to US$16.19

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Robust Earnings May Not Tell The Whole Story For Core Scientific (NASDAQ:CORZ)

Core Scientific, Inc. announced that it expects to receive $75 million in funding from B. Riley Commercial Capital, LLC

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin